(Q38355461)

2 September 2017

1 reference

title

Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: a review of economic evaluations (2006-2014). (English)

1 reference

2 September 2017

David Bin-Chia Wu

1 reference

2 September 2017

Nathorn Chaiyakunapruk

series ordinal

1 reference

2 September 2017

Huey-Yi Chong

series ordinal

1 reference

2 September 2017

Philippe Beutels

series ordinal

1 reference

2 September 2017

language of work or name

English

0 references

publication date

11 February 2015

1 reference

2 September 2017

1 reference

inferred from page(s)

published in

Vaccine

1 reference

2 September 2017

1 reference

2 September 2017

1 reference

2 September 2017

page(s)

1633-1658

1 reference

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Impact of conjugate pneumococcal vaccines on antibiotic resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Impact of conjugate 7-valent vaccination in Belgium: Addressing methodological challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Prevalence of Streptococcus pneumoniae serotypes causing invasive and non-invasive disease in South East Asia: a review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination--a review (2002-2006).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Pneumococcal conjugate vaccination in Canadian infants and children younger than five years of age: Recommendations and expected benefits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Pneumococcal conjugate vaccine: review of cost-effectiveness studies in Australia, North America and Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

New vaccines against otitis media: projected benefits and cost-effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Economic evaluation of pneumococcal conjugate vaccination in The Gambia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the universal immunisation of infants in Brazil.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Economic evaluation of second generation pneumococcal conjugate vaccines in Norway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

The potential cost-effectiveness of infant pneumococcal vaccines in Australia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost effectiveness of child pneumococcal conjugate vaccination in middle-income countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost-effectiveness analysis of pneumococcal conjugate vaccine in Taiwan: a transmission dynamic modeling approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Economic evaluation of vaccination programme of 13-valent pneumococcal conjugate vaccine to the birth cohort in Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

The Health Economic Impact of Universal Infant Vaccination with the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine as Compared with 13-Valent Pneumococcal Conjugate Vaccine in Hong Kong

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost-effectiveness analysis of pneumococcal vaccination in Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Economic impact of pneumococcal conjugate vaccination in Brazil, Chile, and Uruguay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Economic evaluation of universal infant vaccination with 7vPCV in Hong Kong

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost-effectiveness of a 3-dose pneumococcal conjugate vaccine program in the province of Quebec, Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Hereditary alpha-1-antitrypsin deficiency and its clinical consequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Estimating the cost-effectiveness of pneumococcal conjugate vaccination in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Economic evaluation of vaccination programme of 7-valent pneumococcal conjugate vaccine to the birth cohort in Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

7-Valent pneumococcal conjugate vaccine and otitis media: effectiveness of a 2-dose versus 3-dose primary series.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Economic evaluation of universal 7-valent pneumococcal conjugate vaccination in Taiwan: a cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Towards New Broader Spectrum Pneumococcal Vaccines: The Future of Pneumococcal Disease Prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Impact of pneumococcal conjugate vaccines on the incidence of pneumonia in hospitalized children after five years of its introduction in Uruguay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

All-cause pneumonia hospitalizations in children <2 years old in sweden, 1998 to 2012: impact of pneumococcal conjugate vaccine introduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Serotype distribution and antimicrobial resistance of invasive and noninvasive pneumococcal isolates in Tunisia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

The cost-effectiveness of pneumococcal conjugate vaccination in Australia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Outcomes of bacterial meningitis in children: a meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Outcome of meningitis caused by Streptococcus pneumoniae and Haemophilus influenzae type b in children in The Gambia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Seizures and other neurologic sequelae of bacterial meningitis in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Economic evaluation of vaccination programs: the impact of herd-immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Potential impact of accelerating the primary dose of pneumococcal conjugate vaccine in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Evaluation of the Indirect Effects of a Pneumococcal Vaccine in a Community-Randomized Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

An individual-based network model to evaluate interventions for controlling pneumococcal transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Outbreaks of Streptococcus pneumoniae carriage in day care cohorts in Finland - implications for elimination of transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Herd immunity and pneumococcal conjugate vaccine: a quantitative model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Could a single dose of pneumococcal conjugate vaccine in children be effective?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Transmission-dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-valent pneumococcal conjugate vaccine (PCV7)) in older populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Pneumococcal transmission and disease in silico: a microsimulation model of the indirect effects of vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Modeling transmission of multitype infectious agents: application to carriage of Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Vaccination against colonizing bacteria with multiple serotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Modelling transmission, immunity and disease of Haemophilus influenzae type b in a structured population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Potential conflicts of interest in vaccine economics research: a commentary with a case study of pneumococcal conjugate vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Social contacts and mixing patterns relevant to the spread of infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

Have changing pneumococcal vaccination programmes impacted disease in Ontario?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

7-Valent pneumococcal conjugate vaccine and lower respiratory tract infections: effectiveness of a 2-dose versus 3-dose primary series

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.081

10.1016/J.VACCINE.2015.01.081

7 January 2021

Identifiers

DOI

1 reference

2 September 2017

1 reference